Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...
Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that the phase III clinical trial of the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy developed independently by the company for locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations that failed EGFR-TKI treatment has recently completed the enrollment of the first test subjects.